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Maturity onset diabetes of the young (MODY) is a monogenic form of diabetes inherited as an autosomal dominant trait. The
second most common cause is GCK-MODY due to heterozygous mutations in the GCK gene which impair the glucokinase
function through diﬀerent mechanisms such as enzymatic activity, protein stability, and increased interaction with its receptor.
The enzyme normally acts as a glucose sensor in the pancreatic beta cell and regulates insulin secretion. We report here a three-
generation nonobese family diagnosed with diabetes. All aﬀected family members presented with mild hyperglycemia and mostly
slightly elevated hemoglobin A1c values. Genetic testing revealed a novel heterozygous T → C exchange in exon 8 of the GCK gene
which resulted in a phenylalanine330 TTC → serine (TCC)/p.Phe330Ser/F330S substitution.
1.Introduction
MODY is a monogenic disease which accounts for 2–5% of
alldiabetescases.ThemostfrequentformisHNF-1α-MODY
(MODY type 3), which is caused by mutations in the HNF1A
gene encoding hepatic nuclear factor 1α. The second most
frequent form is GCK-MODY (MODY type 2), which has
been shown to be the result of mutations in the GCK gene
[1]. The GCK gene maps to chromosome 7p15.3-p15.1 and
consists of 12 exons that encode the 465-amino-acid protein
glucokinase [2, 3], which is one of four members of the
hexokinase family of enzymes. It catalyzes the phosphoryla-
tion of glucose as the ﬁrst step of glycolysis. Glucokinase is
exclusively expressed in mammalian liver and pancreatic islet
beta cells. The enzyme plays an important regulatory role in
glucose metabolism. As a glucose sensor, it regulates insulin
secretion in the pancreatic β-cell by changing the glucose
phosphorylation rate over a range of physiological glucose
concentrations (4–15mmoL/L; [4]). GCK gene mutations
can cause both hypo- and hyperglycemia. Heterozygous
inactivating mutations cause GCK-MODY, which mostly
presents with mild hyperglycemia and is inherited in an
autosomal dominant fashion [5, 6]. Usually, no diabetes-
related complications such as nephropathy or retinopathy
occur in patients with GCK-MODY. Homozygous or com-
pound heterozygous inactivating GCK mutations result in
a more severe phenotype presenting at birth as permanent
neonatal diabetes mellitus [7–11]. Heterozygous activating
GCK mutations, in contrast, cause persistent hyperinsuline-
mic hypoglycemia of infancy [12–16].
In 1992, GCK was the ﬁrst MODY gene to be linked
to disease in French and UK families [5, 6]. These linkage
studies were quickly followed by the identiﬁcation of the
ﬁrst genetic defects. Meanwhile, over 600 diﬀerent GCK
mutations have been described in many populations, the
majority having been identiﬁed in Europe [17]. Missense,
nonsense, frameshift, and splice site mutations have been
reported, which are distributed throughout the 10 exons
encoding the pancreatic β-cell isoform of the enzyme. There
are no mutational hot spots. Over 250 mutations have been
reported in more than one family [17]. All inactivating
mutations are associated with mild fasting hyperglycemia
while other speciﬁc symptoms are missing. Therefore, GCK-
MODY is likely to be underdiagnosed, and no reliable data2 ISRN Pediatrics
on its prevalence are available. In Caucasians, approximately
2% of the population are diagnosed as having gestational
diabetes and approximately 2–5% of these patients will
have GCK-MODY [18]. This would suggest a population
prevalence of 0.04–0.1%.
The identiﬁcation of a GCK gene mutation is important
for the correct and deﬁnite diagnosis of GCK-MODY. It also
helps the clinician to predict the clinical course of the disease
and to advise appropriate therapy. Since only mild fasting
hyperglycemia and no diabetes-related complications are
usually present, diet is suﬃcient as a therapeutic approach
in most cases [19].
We report a novel heterozygous inactivating GCK gene
mutation in a nonobese family diagnosed with diabetes over
three generations.
2.CaseReport
A 17-year-old, nonobese (BMI 24.3kg/m2) female was
admitted for the evaluation of recurrent syncopes. A blood
glucose proﬁle was obtained, and she was found to be
mildly hyperglycemic (blood glucose values between 6.7 and
10mmoL/L). Hemoglobin A1c was slightly elevated with
6.5% (normal range 4.0–6.0%) or 48mmoL/moL (normal
range 20–42mmoL/moL). A standard oral glucose tolerance
test with 75g of glucose equivalent was performed (Table 1)
with a fasting glucose of 6.5mmoL/L and a 2-hour glucose
of 14.6mmoL/L. The fasting insulin concentration was
3.6μU/mL and 66.1μU/mL after two hours.
Her family history was strongly positive for diabetes. The
patient’s brother, her father, and the grandparents on her
father’s side were diagnosed with diabetes. Her grandmother
was treated with oral antidiabetic medication (glimepiride).
The index patient also reported that she had been diagnosed
with mild hyperglycemia ten years ago, but this had no
therapeutic consequences, and no followup analyses were
performed.
This clinical presentation was highly suggestive of GCK-
MODY. Therefore, a mutation analysis of the GCK gene was
initiated.GenomicDNAofthepatientwasisolated,andPCR
ampliﬁcation of the pancreas-speciﬁc exon 1a as well as of
exons 2–10 of the GCK gene was performed. Sequencing of
the PCR products identiﬁed a novel phenylalanine330 (TTC)
→ serine (TCC)-/p.Phe330Ser-/F330S substitution encoded
by exon 8. The index patient was also screened for type
1 diabetes-speciﬁc antibodies in the context of a Bavarian
diabetes registry (DiMelli). Insulin autoantibodies (IAA),
tyrosinephosphataseantibodies(IA2A),andzinctransporter
antibodies (ZnT8c) were negative. Antibodies against gluta-
matedecarboxylase (GADA) were weakly positive.
Carrier screening of clinically aﬀected family members
revealed the same mutation in the pedigree with the excep-
tion of the grandfather, who has type 2 diabetes mellitus
(Figure 1). The phenotype of the index patient’s brother was
comparable to that of the index patient (BMI 21.5kg/m2,
hemoglobin A1c 6.2%, or 44mmoL/moL). The father of the
index patient was diagnosed with diabetes at 25 years of
age. He also presented with very mild hyperglycemia and
haemoglobin A1c at the upper end of the normal range
Healthy males Healthy females
GCK-MODY males GCK-MODY females
Figure 1: Circle: females, boxes: males, white: healthy, black: GCK-
MODY.
Table 1: Glucose and insulin concentrations during a standard oral
glucose tolerance test with 75g glucose equivalent.
Time
[min.]
Glucose
[mg/dl]
Glucose
[mmol/L]
Insulin
[μU/mL]
0 117 6.5 3.6
30 191 10.6 31.1
60 247 13.7 53.2
120 263 14.6 66.1
(5.9% or 41mmoL/moL). The father’s BMI was 27.8kg/m2.
Despite normal haemoglobin A1c, an antidiabetic treatment
with metformin was started by the father’s diabetologist. The
index patient’s grandmother was diagnosed with diabetes at
the age of 62 years. Her BMI was 30.0kg/m2, and she had a
haemoglobin A1c value of 7.0% or 53mmoL/moL. She was
treatedwithglimepiride.Thegrandfatherwasalsodiagnosed
with diabetes but was not on any antidiabetic medication.
His BMI was 29.8kg/m2 and his haemoglobin A1c never
exceeded 7.0% or 53mmoL/moL. No GCK mutation was
found in him, so his ﬁnal diagnosis is type 2 diabetes
mellitus.
Because of the typical clinical symptoms and the coseg-
regation of the phenotype with the genotype, we conclude
that this novel mutation is a pathogenic one and not a
polymorphism without an eﬀect on protein function.
3. Discussion
So far, more than 620 GCK gene mutations have been
reported in over 1400 patients with GCK-MODY (Table 2),
permanent neonatal diabetes, and hyperinsulinemic hypo-
glycemia [17, 20, 21]. The mutations are spread over
the ten exons of the gene which encode the pancreatic
beta cell isoform of glucokinase (exons 1a and 2–10).ISRN Pediatrics 3
Table 2: Published GCK mutations causing GCK-MODY (MODY 2).
Region Nucleotide and systematic name Protein eﬀect Reference
Islet promoter c.−71G>C— [ 25]
Exon 2 c.106C>T p.Arg36Trp [26]
c.130G>A p.Gly44Ser [27]
c.157G>T p.Ala53Ser [20]
c.182A>C p.Tyr61Ser [28]
c.185T>C p.Val62Ala [21]
c.184G>A p.Val62Met [21, 29]
c.208G>A p.Glu70Lys [20, 30]
Exon 3 c.214G>A p.Gly72Arg [29]
c.239G>C p.Gly80Ala [20]
c.323A>G p.Tyr108Cys [21]
Exon 4 c.391T>C p.Ser131Pro [31]
c.410A>G p.His137Arg [20]
c.437T>G p.Leu146Arg [21]
c.480 482dupTAA p.Asp160 Lys161 ins Asn [32]
Exon 5 c.493C>T p.Leu165Phe [33]
c.502A>C p.Thr168Pro [20]
c.523G>A p.Gly175Arg [20]
c.524G>A p.Gly175Glu [20]
c.544G>T p.Val182Leu [28]
c.562G>A p.Ala188Thr [31]
c.563C>A p.Ala188Glu [21]
Exon 6 c.608T>C p.Val203Ala [30]
c.617C>T p.Thr206Met [33]
c.622G>A p.Ala208Thr [22]
c.626C>T p.Thr209Met [26]
c.629T>C p.Met210Thr [20]
c.637T>C p.Cys213Arg [20]
c.676G>A p.Val226Met [20]
c.682A>G p.Thr228Ala [34]
c.697T>C p.Cys233Arg [28]
c.703A>G p.Met235Val [32]
c.704T>C p.Met235Thr [21]
c.755G>A p.Cys252Tyr [21]
c.766G>A p.Glu256Lys [35]
c.769T>C p.Trp257Arg [31]
c.781G>A p.Gly261Arg [20]
c.787T>C p.Ser263Pro [21]
c.793G>A p.Glu265Lys [28]
c.823C>T p.Arg275Cys [21]
c.835G>C p.Glu279Gln [35]
Exon 8 c.893T>A p.Met298Lys [21]
c.895G>C p.Gly299Arg [35]
c.898G>C p.Glu300Gln [35]
c.898G>A p.Glu300Lys [30]
c.922A>T p.Arg308Trp [32]
c.926T>C p.Leu309Pro [20, 35]
c.1007C>T p.Ser336Leu [20, 34]
c.1016A>G p.Glu339Gly [21, 22]4 ISRN Pediatrics
Table 2: Continued.
Region Nucleotide and systematic name Protein eﬀect Reference
Exon 9 c.1099G>A p.Val367Met [20, 26]
c.1129C>T p.Arg377Cys [21, 22]
c.1136C>T p.Ala379Val [28]
c.1148C>T p.Ser383Leu [21]
c.1232C>T p.Ser411Phe [21]
c.1240A>G p.Lys414Glu [20, 36]
Exon 10 c.1258A>G p.Lys420Glu [28]
c.1358C>T p.Ser453Leu [22]
c.1364T>A p.Val455Glu [37]
Only few mutations have been detected in exon 1a, since
most laboratories only screen for GCK mutations in exons
2–10 [18]. Missense, nonsense, frameshift, and splice site
mutations have been reported. There are no mutation hot
spots. Most of the mutations are private, although 255
mutations have been described in more than one family
[18, 22]. We here report a novel heterozygous p.Phe330Ser
mutationencodedbyGCK exon8whichresultsinthetypical
GCK-MODY phenotype. The mutation was found in three
generations of a nonconsanguineous family, following an
autosomal dominant inheritance pattern.
A GCK gene polymorphism with functional signiﬁcance
also has been reported in the literature [23, 24]. The G>A
exchange at position −30 of the beta-cell-speciﬁc promoter
(rs1799884) has been shown to be associated with increased
fastingglucoselevelsinyoungadultsandinpregnantwomen
as well as an increased birth weight of their oﬀspring [23].
The identiﬁcation of a pathogenic GCK gene mutation
is important for the correct and deﬁnite diagnosis of
GCK-MODY and helps the clinician to predict the disease
course and to initiate the appropriate therapy. Since only
mild fasting hyperglycemia and usually no diabetes-related
complications are present in patients with GCK-MODY, diet
issuﬃcientasatherapeuticapproachinmostcases[19].This
may signiﬁcantly improve the patient’s quality of life.
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